Qtern saxagliptin/dapagliflozin regulatory update

The European Commission approved Qtern saxagliptin/dapagliflozin from AstraZeneca to treat adult Type II diabetics. The product is indicated to improve glycemic control when metformin and/or sulphonylurea and 1 of Qtern’s components alone do not provide adequate control or when patients are taking both drugs separately. Qtern is an oral fixed-dose combination of Forxiga dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and Onglyza saxagliptin, a dipeptidyl peptidase-4 ( DPP-4; CD26) inhibitor. ...